1230 related articles for article (PubMed ID: 25936945)
21. Virtual screening of B-Raf kinase inhibitors: A combination of pharmacophore modelling, molecular docking, 3D-QSAR model and binding free energy calculation studies.
Zhang W; Qiu KX; Yu F; Xie XG; Zhang SQ; Chen YJ; Xie HD
Comput Biol Chem; 2017 Oct; 70():186-190. PubMed ID: 28892749
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
[TBL] [Abstract][Full Text] [Related]
23. Computational Studies of bis-2-Oxoindoline Succinohydrazides and their In Vitro Cytotoxicity.
Jarapula R; Badavath VN; Rekulapally S; Manda S
Curr Comput Aided Drug Des; 2020; 16(3):270-280. PubMed ID: 30652647
[TBL] [Abstract][Full Text] [Related]
24. Structure-based quantitative structure-activity relationship studies of checkpoint kinase 1 inhibitors.
Du J; Xi L; Lei B; Lu J; Li J; Liu H; Yao X
J Comput Chem; 2010 Nov; 31(15):2783-93. PubMed ID: 20839304
[TBL] [Abstract][Full Text] [Related]
25. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
26. 3D-QSAR studies on Maslinic acid analogs for Anticancer activity against Breast Cancer cell line MCF-7.
Alam S; Khan F
Sci Rep; 2017 Jul; 7(1):6019. PubMed ID: 28729623
[TBL] [Abstract][Full Text] [Related]
27. QSAR Modeling of the Arylthioindole Class of Colchicine Polymerization Inhibitors as Anticancer Agents.
Habibpour E; Ahmadi S
Curr Comput Aided Drug Des; 2017; 13(2):143-159. PubMed ID: 28120704
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, biological evaluation, and molecular docking studies of novel 1,3,4-oxadiazole derivatives possessing benzotriazole moiety as FAK inhibitors with anticancer activity.
Zhang S; Luo Y; He LQ; Liu ZJ; Jiang AQ; Yang YH; Zhu HL
Bioorg Med Chem; 2013 Jul; 21(13):3723-9. PubMed ID: 23673215
[TBL] [Abstract][Full Text] [Related]
29. Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold.
Hernández-Campos A; Velázquez-Martínez I; Castillo R; López-Vallejo F; Jia P; Yu Y; Giulianotti MA; Medina-Franco JL
Chem Biol Drug Des; 2010 Sep; 76(3):269-76. PubMed ID: 20572809
[TBL] [Abstract][Full Text] [Related]
30. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
31. Pharmacoinformatic Approaches to Design Novel Inhibitors of Protein Kinase B Pathways in Cancer.
Akhtar N; Jabeen I
Curr Cancer Drug Targets; 2018; 18(9):830-846. PubMed ID: 28669343
[TBL] [Abstract][Full Text] [Related]
32. Novel pyrrolopyridinone derivatives as anticancer inhibitors towards Cdc7: QSAR studies based on dockings by solvation score approach.
Wu X; Zeng H; Zhu X; Ma Q; Hou Y; Wu X
Eur J Pharm Sci; 2013 Nov; 50(3-4):323-34. PubMed ID: 23933111
[TBL] [Abstract][Full Text] [Related]
33. Syntheses of novel β-carboline derivatives and the activities against five tumor-cell lines.
Bai B; Li XY; Liu L; Li Y; Zhu HJ
Bioorg Med Chem Lett; 2014 Jan; 24(1):96-8. PubMed ID: 24345445
[TBL] [Abstract][Full Text] [Related]
34. Structure-based pharmacophore models to probe anticancer activity of inhibitors of protein kinase B-beta (PKB β).
Akhtar N; Jabeen I; Jalal N; Antilla J
Chem Biol Drug Des; 2019 Mar; 93(3):325-336. PubMed ID: 30354009
[TBL] [Abstract][Full Text] [Related]
35. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
[TBL] [Abstract][Full Text] [Related]
36. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
[TBL] [Abstract][Full Text] [Related]
37. 3D-QSAR and docking studies on ursolic acid derivatives for anticancer activity based on bladder cell line T24 targeting NF-kB pathway inhibition.
Yadav D; Nath Mishra B; Khan F
J Biomol Struct Dyn; 2019 Sep; 37(14):3822-3837. PubMed ID: 30261824
[TBL] [Abstract][Full Text] [Related]
38. Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development.
Hameed R; Khan A; Khan S; Perveen S
Anticancer Agents Med Chem; 2019; 19(5):592-598. PubMed ID: 30306880
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
Chen DX; Huang J; Liu M; Xu YG; Jiang C
Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
[TBL] [Abstract][Full Text] [Related]
40. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.
Caballero J; Alzate-Morales JH; Vergara-Jaque A
J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
